What it sells
Robotic human cell manufacturing
Business model breakdown
Buyer: who owns the budget?
Cell and regenerative medicine therapy developers (e.g. Aspen Neuroscience, Novadip, Rinri, StemSight) outsourcing manufacturing.
Trigger: what makes them buy now?
Therapies work in clinic but manual production does not scale or is too costly for Phase 3 and commercialization.
Workflow: what inputs become what output?
Request info, scoping study and "Proof of Value" on the iDEM platform, then scale production in Mytos automated cleanroom site (UK).
Economics: what it saves and how it charges
Automated CDMO: claims 4x faster scaling, 10x batches per cleanroom, 40% lower cost per batch, 10x fewer FTE hours.
Distribution: how it reaches customers
Direct enterprise sales with partnerships and collaborations (Request Info form).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2018 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.